Silence Therapeutics Net Worth
Silence Therapeutics Net Worth Breakdown | SLN |
Silence Therapeutics Net Worth Analysis
Silence Therapeutics' net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including Silence Therapeutics' financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of Silence Therapeutics' overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform Silence Therapeutics' net worth analysis. One common approach is to calculate Silence Therapeutics' market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares Silence Therapeutics' stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing Silence Therapeutics' net worth. This approach calculates the present value of Silence Therapeutics' future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of Silence Therapeutics' cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate Silence Therapeutics' net worth. This involves comparing Silence Therapeutics' financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into Silence Therapeutics' net worth relative to its peers.
Enterprise Value |
|
To determine if Silence Therapeutics is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Silence Therapeutics' net worth research are outlined below:
| Silence Therapeutics generated a negative expected return over the last 90 days | |
| Silence Therapeutics has high historical volatility and very poor performance | |
| Silence Therapeutics has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the last year's revenue of 25.38 M. Reported Net Loss for the year was (50.31 M) with profit before taxes, overhead, and interest of 6.62 M. | |
| Silence Therapeutics PLC has about 51.56 M in cash with (39.35 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.72. | |
| Roughly 63.0% of the company shares are owned by institutional investors | |
| Latest headline from thelincolnianonline.com: Silence Therapeutics Given Buy Rating at Chardan Capital |
Silence Therapeutics Quarterly Good Will |
|
Silence Therapeutics uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Silence Therapeutics PLC. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Silence Therapeutics' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 20th of March 2024 Upcoming Quarterly Report | View | |
| 21st of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 20th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Know Silence Therapeutics' Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Silence Therapeutics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Silence Therapeutics PLC backward and forwards among themselves. Silence Therapeutics' institutional investor refers to the entity that pools money to purchase Silence Therapeutics' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Ikarian Capital, Llc | 2024-09-30 | 587.3 K | Parkman Healthcare Partners Llc | 2024-09-30 | 497.9 K | Saturn V Capital Management Llc | 2024-09-30 | 481.1 K | 5am Venture Management, Llc | 2024-09-30 | 476.2 K | Point72 Asset Management, L.p. | 2024-09-30 | 467.8 K | Citadel Advisors Llc | 2024-09-30 | 436.7 K | Woodline Partners Lp | 2024-09-30 | 406.9 K | Cormorant Asset Management, Llc | 2024-09-30 | 400 K | Duquesne Family Office Llc | 2024-09-30 | 387.4 K | Tcg Crossover Management, Llc | 2024-09-30 | 3 M | Lombard Odier Asset Management Usa Corp | 2024-09-30 | 2.7 M |
Follow Silence Therapeutics' market capitalization trends
The company currently falls under 'Small-Cap' category with a total capitalization of 354.11 M.Market Cap |
|
Project Silence Therapeutics' profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.50) | (0.53) | |
| Return On Capital Employed | (0.65) | (0.68) | |
| Return On Assets | (0.46) | (0.48) | |
| Return On Equity | (2.54) | (2.41) |
When accessing Silence Therapeutics' net worth, it's important to look at multiple sources and consider different scenarios. For example, gross profit margin measures Silence Therapeutics' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Silence Therapeutics' profitability and make more informed investment decisions.
Evaluate Silence Therapeutics' management efficiency
Silence Therapeutics PLC has Return on Asset of (0.2154) % which means that on every $100 spent on assets, it lost $0.2154. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of (0.6428) %, meaning that it generated no profit with money invested by stockholders. Silence Therapeutics' management efficiency ratios could be used to measure how well Silence Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. As of the 13th of December 2024, Return On Tangible Assets is likely to drop to -0.53. In addition to that, Return On Capital Employed is likely to drop to -0.68. At this time, Silence Therapeutics' Fixed Asset Turnover is very stable compared to the past year. As of the 13th of December 2024, Asset Turnover is likely to grow to 0.28, while Non Current Assets Total are likely to drop about 8.2 M.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 0.46 | 0.44 | |
| Tangible Book Value Per Share | 0.24 | 0.23 | |
| Enterprise Value Over EBITDA | (9.10) | (9.55) | |
| Price Book Value Ratio | 29.71 | 31.20 | |
| Enterprise Value Multiple | (9.10) | (9.55) | |
| Price Fair Value | 29.71 | 31.20 | |
| Enterprise Value | 452.9 M | 475.5 M |
The decision-making processes within Silence Therapeutics are key to its success in a competitive market. By evaluating these processes, we assess the stock's potential for future gains.
Enterprise Value Revenue 5.7293 | Revenue 17.9 M | Quarterly Revenue Growth (0.93) | Revenue Per Share 0.429 | Return On Equity (0.64) |
Silence Therapeutics Corporate Filings
6K | 9th of December 2024 A report filed by foreign private issuers with SEC. A foreign private issuer is a non-U.S. company with securities traded on U.S. exchanges. | ViewVerify |
13A | 12th of November 2024 An amended filing to the original Schedule 13G | ViewVerify |
| 22nd of October 2024 Other Reports | ViewVerify | |
| 14th of May 2024 Other Reports | ViewVerify |
Silence Therapeutics Earnings per Share Projection vs Actual
Silence Therapeutics Corporate Management
| John Strafford | Alliance Devel | Profile | |
| Rhonda Hellums | Chief Officer | Profile | |
| Eric Floyd | VP Assurance | Profile | |
| Gem Hopkins | Head Communications | Profile | |
| Gianine Esposito | Chief Officer | Profile | |
| Giles MD | Head VP | Profile | |
| Jrgen Wittendorff | VP Manufacturing | Profile |
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Silence Therapeutics PLC. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis. You can also try the Piotroski F Score module to get Piotroski F Score based on the binary analysis strategy of nine different fundamentals.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Silence Therapeutics. If investors know Silence will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Silence Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.76) | Revenue Per Share 0.429 | Quarterly Revenue Growth (0.93) | Return On Assets (0.22) | Return On Equity (0.64) |
The market value of Silence Therapeutics PLC is measured differently than its book value, which is the value of Silence that is recorded on the company's balance sheet. Investors also form their own opinion of Silence Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Silence Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Silence Therapeutics' market value can be influenced by many factors that don't directly affect Silence Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Silence Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Silence Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Silence Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.